CareDx Introduces AlloCell: Cell Therapy Surveillance
Allogeneic cell therapy is a rapidly growing area of clinical development with research underway for applications in oncology, cardiovascular, neurological, autoimmune, and infectious disease. In oncology, initial CAR T-cell therapies were created by genetically modifying a patient’s own immune cells to target specific cancer cells before transplanting them back into the patient. With allogeneic therapies, the CAR T-cells are manufactured from cells of healthy donors for “off-the-shelf” use in patients, simplifying the manufacturing process, and reducing patients’ wait time from diagnosis to treatment.
“Allogeneic CAR-T is the next stage of immuno-oncology therapy, and we expect it to have a transformative impact on our patients with an increasing range of indications,” said
“With the goal of improving transplant patient outcomes at the core of what we do, we are glad to begin cellular therapy collaborations to help patients with life-saving immune cell transplants,” said
Chief Marketing Officer
Source: CareDx, Inc.